UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds

Annals of oncology, 2021-07, Vol.32 (7), p.831-832

2021

Volltextzugriff (PDF)

Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients

World journal of urology, 2022-01, Vol.40 (1), p.111-118

2022

Volltextzugriff (PDF)

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial

Frontiers in oncology, 2023-08, Vol.13, p.1246603

2023

Volltextzugriff (PDF)

Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment

Annals of oncology, 2018-10, Vol.29, p.viii281-viii282

2018

Volltextzugriff (PDF)

A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii418-viii418

2018

Volltextzugriff (PDF)

Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii134-viii135

2018

Volltextzugriff (PDF)

Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features

American journal of kidney diseases, 1998-01, Vol.31 (1), p.108-115

1998

Volltextzugriff (PDF)

1197P Ex vivo basket study reports patient-specific sensitivity to carboplatin versus cisplatin in lung, ovarian and bladder cancer

Annals of oncology, 2024-09, Vol.35, p.S771-S771

2024

Volltextzugriff (PDF)

130P Ipilimumab plus nivolumab (Ipi+Nivo) in patients with tumors harboring high tumor mutational burden or load (TMB/TML-H): Results from the Drug Rediscovery Protocol (DRUP)

Annals of oncology, 2024-09, Vol.35, p.S267-S267

2024

Volltextzugriff (PDF)

859P - Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

Annals of oncology, 2019-10, Vol.30, p.v335-v336

2019

Volltextzugriff (PDF)

859PPain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

Annals of oncology, 2019-10, Vol.30, p.v335-v336

2019

Volltextzugriff (PDF)

694P Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors

Annals of oncology, 2023-10, Vol.34, p.S483-S484

2023

Volltextzugriff (PDF)

95P Optimizing selection of experimental treatment for patients with advanced cancer using whole genome sequencing

Annals of oncology, 2021-09, Vol.32, p.S397-S397

2021

Volltextzugriff (PDF)

143 (PB131): Preliminary Safety and Pharmacokinetics of the MET-TKI DO-2 in Patients with Advanced Solid Tumors Harboring MET Aberrations: A Phase I Study

European journal of cancer (1990), 2024-10, Vol.211, p.114665, Article 114665

2024

Volltextzugriff (PDF)

1630P A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2024-09, Vol.35, p.S984-S984

2024

Volltextzugriff (PDF)

1780TiP A phase II clinical study to assess efficacy of induction ipilimumab/nivolumab to spare the bladder in urothelial bladder cancer (INDI-BLADE)

Annals of oncology, 2022-09, Vol.33, p.S1351

2022

Volltextzugriff (PDF)

1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer

Annals of oncology, 2020-09, Vol.31, p.S706-S707

2020

Volltextzugriff (PDF)

813PTreatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

LBA29Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

LBA29 - Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v865-v866

2019

Volltextzugriff (PDF)

Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v865-v866

2019

Volltextzugriff (PDF)

1172PA first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

412PDClinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

MN blood group, a genetic marker for essential arterial hypertension in young adults

European heart journal, 1995-09, Vol.16 (9), p.1269-1276

1995

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(23)
Biological And Medical Sciences
(14)
Humans
(13)
Physical Sciences
(12)
Astronomy & Astrophysics
(10)
Aged
(8)
Female
(8)
Fundamental And Applied Biological Sciences. Psychology
(7)
Male
(7)
Medical Sciences
(7)
Physics
(7)
Adult
(6)
Middle Aged
(6)
Cardiac & Cardiovascular Systems
(5)
Cardiovascular System & Cardiology
(5)
Fruits
(5)
Plant Sciences
(5)
Spermatophyta
(5)
Systematics
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds

Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial

Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment

A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors

Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features

1197P Ex vivo basket study reports patient-specific sensitivity to carboplatin versus cisplatin in lung, ovarian and bladder cancer

130P Ipilimumab plus nivolumab (Ipi+Nivo) in patients with tumors harboring high tumor mutational burden or load (TMB/TML-H): Results from the Drug Rediscovery Protocol (DRUP)

859P - Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

859PPain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

694P Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors

95P Optimizing selection of experimental treatment for patients with advanced cancer using whole genome sequencing

143 (PB131): Preliminary Safety and Pharmacokinetics of the MET-TKI DO-2 in Patients with Advanced Solid Tumors Harboring MET Aberrations: A Phase I Study

1630P A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)

1780TiP A phase II clinical study to assess efficacy of induction ipilimumab/nivolumab to spare the bladder in urothelial bladder cancer (INDI-BLADE)

1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer

813PTreatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment

LBA29Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

LBA29 - Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

1172PA first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors

412PDClinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

MN blood group, a genetic marker for essential arterial hypertension in young adults

Suchergebnisse filtern